Compact brain-dedicated PET achieves amyloid quantification equivalent to full-body PET at 85% cost reduction
Summary
Positrigo published validation data for their NeuroPET compact brain-dedicated PET scanner in 60 participants comparing amyloid PET quantification to conventional full-body PET at major research centers. NeuroPET achieved 96% concordance with conventional PET for amyloid burden classification (positive vs. negative) with a centiloid quantification correlation of r=0.97. Installation requires a standard consultation room with no cyclotron, enabling deployment in neurology practices at 85% lower total cost than conventional PET infrastructure.
Why it matters
Equivalent amyloid quantification accuracy at 85% lower cost with standard-room installation is the breakthrough needed to scale Alzheimer's biomarker testing as lecanemab and donanemab adoption grows. Conventional PET infrastructure serves perhaps 5% of patients who need amyloid imaging; NeuroPET could reach the other 95% at community neurology centers.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial